Latest News

Genedrive’s inclusion in a Public Health England framework pact positive for future revenues, says b


Genedrive PLC’s (LON:GDR) inclusion in a Public Health England framework agreement for diagnostic equipment and services is very positive, said Peel Hunt analysts in a broker note.

“Whilst this is an early indication on future, potential contracts, we consider it a very positive development towards future revenues,” the broker said, retaining its ‘buy’ recommendation.

The framework allows Public Health England, as the sole buyer, to issue call-off orders for products and services for an estimated four-year period, up to a combined value of £3bn, it noted, although it added that about 112 suppliers had been successful.

“The focus today is likely to be on the read-across to coronavirus testing revenues (where we believe Genedrive’s proprietary and stable ‘PCR bead chemistry’ lends itself very well to high-throughput testing formats, whilst helping overcome challenges with wider distribution/logistics).

“However, we consider this good news for the underlying business too (which in our view has some differentiated offerings from the ‘pure-play Covid stocks).”

Britcoin? Bank of England and Treasury to explore central bank digital currency

Previous article

Vanguard looks to disrupt UK financial advice market

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News